Article in Science advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
14 authors.
Tala AzzamDepartment of Biochemistry, Emory University School of Medicine, Atlanta, GA 30322, USA.ORCID 0000-0001-8739-7861
Jonathan J DuDepartment of Biochemistry, Emory University School of Medicine, Atlanta, GA 30322, USA.ORCID 0000-0002-7750-4413
Maria W FlowersDepartment of Biochemistry, Emory University School of Medicine, Atlanta, GA 30322, USA.ORCID 0000-0002-1814-7049
Adeela V AliDepartment of Biochemistry, Emory University School of Medicine, Atlanta, GA 30322, USA.ORCID 0009-0006-3120-5924
Jeremy C HunnDepartment of Biochemistry, Emory University School of Medicine, Atlanta, GA 30322, USA.
Nina VijayvargiyaDepartment of Biochemistry, Emory University School of Medicine, Atlanta, GA 30322, USA.
Rushil KnagaramDepartment of Biochemistry, Emory University School of Medicine, Atlanta, GA 30322, USA.ORCID 0009-0006-0397-9092
Marek BogaczDepartment of Biochemistry, Emory University School of Medicine, Atlanta, GA 30322, USA.
Kino E MaravillasDepartment of Biochemistry, Emory University School of Medicine, Atlanta, GA 30322, USA.ORCID 0000-0002-8547-359X
Diego E SastreDepartment of Biochemistry, Emory University School of Medicine, Atlanta, GA 30322, USA.ORCID 0000-0003-2010-5398
James K FieldsInstitute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.ORCID 0000-0001-5923-108X
Ardalan MirzaeiSydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia.ORCID 0000-0002-1398-0648
Brian G PierceUniversity of Maryland Institute for Bioscience and Biotechnology Research, Rockville, MD 20850, USA.ORCID 0000-0003-4821-0368
Eric J SundbergDepartment of Biochemistry, Emory University School of Medicine, Atlanta, GA 30322, USA.ORCID 0000-0003-0478-3033
Funding
Rationalizing glycoengineering strategies for immunotherapeutic antibodiesR01AI149297 · NIAID · EMORY UNIVERSITY · PI JEFFREY Victor RAVETCH, ERIC JOHN SUNDBERG · 2020 to 2026
$3.7M
High resolution modeling and design of immune recognitionR35GM144083 · NIGMS · UNIV OF MARYLAND, COLLEGE PARK · PI Brian G. Pierce · 2022 to 2026
$1.6M
Phase II SER-CAT Optimization: Acquisition of a next generation area detectorS10RR028976 · NCRR · UNIVERSITY OF GEORGIA · PI WANG, BI-CHENG · 2010 to 2010
$1.5M
Acquisition of a High Precision Micro Diffractometer to Support NIH funded Research at SER-CATS10OD027000 · OD · UNIVERSITY OF GEORGIA · PI ROSE, JOHN PATRICK · 2019 to 2019
$600k
Acquition of a microdiffractometer for SER-CATS10RR025528 · NCRR · UNIVERSITY OF GEORGIA · PI ROSE, JOHN PATRICK · 2009 to 2009
Redesigning protein-protein interfaces is an important tool for developing therapeutic strategies. Interfaces can be redesigned by in silico screening, which allows for efficient sampling of a large protein space before experimental validation. However, computational costs limit the number of combinations that can be reasonably sampled. Here, we present combinatorial tyrosine (Y)/serine (S) selection (combYSelect), a computational approach combining in silico determination of the change in binding free energy (ΔΔ
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Combinatorially restricted computational design of protein-protein interfaces to produce IgG heterodimers. · full record | OpenQuestion